Ordinary Fully Paid Deferred Settlement

Ordinary Fully Paid Deferred Settlement

BP8DF · AU · Healthcare / Drug Manufacturers - Specialty & Generic

0.014AUD+0.00 (+7.69%)

Price History

Full chart

Market Stats

Previous Close0.013
Open0.014
Day Range0.014 – 0.014
52-Week Range0.01 – 0.03
Volume30.00K
Market Cap3.29M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield0.00%
Beta0.53
50-Day Avg0.0153
200-Day Avg0.0179

About

Ocean Sciences Ltd, together with its subsidiaries, engages in sourcing, producing, marketing, and selling traditional medicines in Australia, Singapore, China, and Southeast Asia. The company's products include raw bird's nest and processed bird's nest products, and Caulerpa Lentillifera, sea grapes, and seaweeds. Its products are used in the food, nutrition, healthcare, health supplements, cosmetics and personal care industries. Ocean Sciences Ltd was formerly known as BPH Global Ltd and changed its name to Ocean Sciences Ltd in September 2026. The company was incorporated in 1984 and is based in Melbourne, Australia.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Francesco Cannavo
  • Headquarters365 Little Collins Street, Melbourne, VIC, Australia, 3000, Australia
  • Websitehttps://bphglobal.com

Leadership

  • Mr. Francesco CannavoInterim Executive Chairman
  • Mr. Matthew Robert LeonardMD & Executive Director
  • Mr. Chow-Yee KohChief Financial Officer · b. 1976
  • Ms. Ifat MazouzChief Scientific Officer
  • Mr. Justyn Peter Stedwell B.Com.Company Secretary · b. 1981

Financials

Income Statement

Currency: AUD2022-06-302023-06-302024-06-30
Total Revenue14.35M339109.97K
Growth (%)--100.00%+32338.05%
Cost of Revenue12.07M-91.69K
Gross Profit2.29M33918.27K
Gross Margin15.93%100.00%16.61%
Operating Expense5.24M2.51M1.77M
Operating Income-2.95M-2.51M-1.75M
Operating Margin-20.57%-740745.13%-1595.85%
EBITDA-2.65M-2.49M-2.14M
EBITDA Margin-18.44%-734995.28%-1948.50%
Net Income-3.69M-4.83M-2.65M
Net Income Margin-25.71%-1424179.35%-2411.51%
R&D279.32K49.92K-
R&D as % of Total Revenue1.95%14726.25%-
Interest Expense62.64K-20.41K
Interest Expense % of Total Revenue0.44%-18.56%

Balance Sheet

Currency: AUD2022-06-302023-06-302024-06-30
Total Assets7.62M1.47M283.46K
Total Liabilities2.44M1.19M1.97M
Total Equity3.20M20.13K-1.41M
Cash624.96K510.22K133.62K
Net Debt551.18K-375.02K

Cash Flow

Currency: AUD2022-06-302023-06-302024-06-30
Financing Cash Flow281.27K1.38M703.75K
Capital Expenditure914.21K58.79K0
Free Cash Flow-4.93M-1.49M-1.26M

Key Statistics & Ratios

Market Cap3.29M
Enterprise Value3.59M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.96
Price / Book2.63
EPS-0.01
Book Value-0.004
Revenue (TTM)3.44M
Gross Profit (TTM)63.97K
EBITDA-1.76M
Profit Margin-51.91%
Operating Margin-37.62%
Return on Equity0.00%
Return on Assets-115.63%
Shares Outstanding235.35M
Shares Float131.07M
Beta0.53
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Sep 15, 20261:10
  • May 28, 20241:5
  • Jul 1, 20151:2
  • Sep 8, 20141:22